Publications
Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A : Guardian 10 trial results
M Joseph John 1, Prantar Chakrabarti 2, Shashikant Apte 3, Maitreyee Bhattacharyya 4, Chandrakala S 5, Trine Hansen 6, Rohan Kolla 7, Cecil Ross 8, Tulika Seth 9, Neeraj Siddharthan 10, Aby Abraham 11 Abstract
Background: Hemophilia A is an X chromosome-linked bleeding disorder caused by the deficiency of coagulation factor VIII (FVIII). The majority of the Indian population with hemophilia A use plasma-derived clotting factors and, in some instances, fresh frozen plasma and cryoprecipitate. Safer and more efficient treatment options are needed for this group of patients.
Objectives: To assess the safety of turoctocog alfa, a third-generation recombinant FVIII molecule, for the treatment and prophylaxis of bleeding episodes in previously treated Indian patients with moderate or severe hemophilia A.